Journal of Clinical Oncology, Vol 16, 642-650, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients

WP Steward, J von Pawel, U Gatzemeier, P Woll, N Thatcher, G Koschel, L Clancy, J Verweij, R de Wit, W Pfeifer, J Fennelly, M von Eiff and J Frisch
Department of Oncology, Leicester Royal Infirmary, United Kingdom. william.steward@uni.romp.msmail.lri-tr.trent.nhs.uk

PURPOSE: To assess whether granulocyte-macrophage colony-stimulating factor (GM-CSF) reduces the toxicity of chemotherapy and alters delivered dose-intensity. To assess the feasibility of dose- intensification of chemotherapy in small-cell lung cancer (SCLC) and determine whether it has an impact on outcome. MATERIALS AND METHODS: Patients with good- or intermediate-prognosis SCLC entered a prospective multicenter study that involved a 2 x 2 factorial design with randomization to six cycles of chemotherapy with ifosfamide 5 g/m2, carboplatin 300 mg/m2, etoposide 120 mg/m2 intravenously (I.V.) on days 1 and 2 and 240 mg/m2 orally on day 3, and vincristine 0.5 mg/m2 I.V. on day 15 (V-ICE) every 3 weeks (intensified arm) or every 4 weeks (standard arm). A second double-blind randomization to subcutaneous GM-CSF (250 microg/m2/d) or placebo for 14 days between chemotherapy cycles was made. RESULTS: Three hundred patients were entered. Myelosuppression was the main toxicity, with no significant difference in the incidence or grade between treatment groups. The incidence of febrile neutropenia and bacteriologically confirmed sepsis was unaffected by chemotherapy schedule or use of GM-CSF. Twenty-six percent greater dose-intensity was delivered in the intensified arm, with a trend for greater dose-intensity for those who received GM-CSF. Eighty-three percent of patients achieved a response (51% complete response [CR] rate), with no significant difference in response rates between treatment groups. Survival was significantly increased in the intensified compared with the standard arm (P = .0014); median survival rates were 443 versus 351 days and 2-year survival rates were 33% versus 18%, respectively. CONCLUSION: GM-CSF does not reduce the incidence of complications from myelosuppression of aggressive chemotherapy. Dose intensification of V-ICE to a 3-week schedule in SCLC is not associated with increased toxicity, but appears to improve survival significantly. Future studies should aim to deliver chemotherapy in maximal-tolerated dose-intensities.

This article has been cited by other articles:

				S. Leyvraz, S. Pampallona, G. Martinelli, F. Ploner, L. Perey, S. Aversa, S. Peters, P. Brunsvig, A. Montes, A. Lange, et al. A Threefold Dose Intensity Treatment With Ifosfamide, Carboplatin, and Etoposide for Patients With Small Cell Lung Cancer: A Randomized Trial J Natl Cancer Inst, April 16, 2008; 100(8): 533 - 541. [Abstract] [Full Text] [PDF]

				L. Sung, P. C. Nathan, S. M.H. Alibhai, G. A. Tomlinson, and J. Beyene Meta-analysis: Effect of Prophylactic Hematopoietic Colony-Stimulating Factors on Mortality and Outcomes of Infection Ann Intern Med, September 18, 2007; 147(6): 400 - 411. [Abstract] [Full Text] [PDF]

				J. L. Pujol, J. L. Breton, R. Gervais, M.-L. Tanguy, E. Quoix, P. David, H. Janicot, V. Westeel, S. Gameroff, J. Geneve, et al. Phase III Double-Blind, Placebo-Controlled Study of Thalidomide in Extensive-Disease Small-Cell Lung Cancer After Response to Chemotherapy: An Intergroup Study FNCLCC cleo04 IFCT 00-01 J. Clin. Oncol., September 1, 2007; 25(25): 3945 - 3951. [Abstract] [Full Text] [PDF]

				G. Crivellari, S. Monfardini, S. Stragliotto, D. Marino, and S. M. L. Aversa Increasing Chemotherapy in Small-Cell Lung Cancer: From Dose Intensity and Density to Megadoses Oncologist, January 1, 2007; 12(1): 79 - 89. [Abstract] [Full Text] [PDF]

				P Pedrazzoli, J. Ledermann, J-P Lotz, S Leyvraz, M Aglietta, G Rosti, K. Champion, S Secondino, F Selle, N Ketterer, et al. High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults Ann. Onc., October 1, 2006; 17(10): 1479 - 1488. [Abstract] [Full Text] [PDF]

				D. De Ruysscher, M. Pijls-Johannesma, J. Vansteenkiste, A. Kester, I. Rutten, and P. Lambin Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer Ann. Onc., April 1, 2006; 17(4): 543 - 552. [Abstract] [Full Text] [PDF]

				Y. Iwasaki, K. Nagata, M. Nakanishi, A. Natuhara, Y. Kubota, M. Ueda, T. Arimoto, and H. Hara Double-Cycle, High-Dose Ifosfamide, Carboplatin, and Etoposide Followed by Peripheral Blood Stem-Cell Transplantation for Small Cell Lung Cancer Chest, October 1, 2005; 128(4): 2268 - 2273. [Abstract] [Full Text] [PDF]

				P. Lorigan, P. J. Woll, M. E. R. O'Brien, L. F. Ashcroft, M. R. Sampson, and N. Thatcher Randomized Phase III Trial of Dose-Dense Chemotherapy Supported by Whole-Blood Hematopoietic Progenitors in Better-Prognosis Small-Cell Lung Cancer J Natl Cancer Inst, May 4, 2005; 97(9): 666 - 674. [Abstract] [Full Text] [PDF]

				J.N. Munck Shorter is not Better J. Clin. Oncol., April 15, 2003; 21(8): 1648 - 1648. [Full Text] [PDF]

				G. R. Simon and H. Wagner Small Cell Lung Cancer Chest, January 1, 2003; 123(1_suppl): 259S - 271S. [Abstract] [Full Text] [PDF]

				S. G. Spiro and J. C. Porter Lung Cancer--Where Are We Today?: Current Advances in Staging and Nonsurgical Treatment Am. J. Respir. Crit. Care Med., November 1, 2002; 166(9): 1166 - 1196. [Abstract] [Full Text] [PDF]

				E. Galani, P. A. Ellis, and P. G. Harper Small-Cell Lung Cancer, High Growth Rate, High Response Rate to Chemotherapy: Ideal for High-Dose Chemotherapy? J. Clin. Oncol., October 1, 2002; 20(19): 3941 - 3943. [Full Text] [PDF]

				V. C. G. Tjan-Heijnen, D. J. T. Wagener, and P. E. Postmus An analysis of chemotherapy dose and dose-intensity in small-cell lung cancer: lessons to be drawn Ann. Onc., October 1, 2002; 13(10): 1519 - 1530. [Abstract] [Full Text] [PDF]

				A. Ardizzoni, V. C.G. Tjan-Heijnen, P. E. Postmus, E. Buchholz, B. Biesma, H. Karnicka-Mlodkowska, R. Dziadziuszko, J. Burghouts, J. P. van Meerbeeck, S. Gans, et al. Standard Versus Intensified Chemotherapy With Granulocyte Colony-Stimulating Factor Support in Small-Cell Lung Cancer: A Prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial--08923 J. Clin. Oncol., October 1, 2002; 20(19): 3947 - 3955. [Abstract] [Full Text] [PDF]

				K. Osterlind Chemotherapy in small cell lung cancer Eur. Respir. J., December 1, 2001; 18(6): 1026 - 1043. [Abstract] [Full Text] [PDF]

				B. E. Johnson Is More Better? Chemotherapy for Patients With Extensive-Stage Small-Cell Lung Cancer J Natl Cancer Inst, February 21, 2001; 93(4): 254 - 255. [Full Text] [PDF]

				J.-L. Pujol, J.-P. Daures, A. Riviere, E. Quoix, V. Westeel, X. Quantin, J.-L. Breton, E. Lemarie, M. Poudenx, B. Milleron, et al. Etoposide Plus Cisplatin With or Without the Combination of 4'-Epidoxorubicin Plus Cyclophosphamide in Treatment of Extensive Small-Cell Lung Cancer: a French Federation of Cancer Institutes Multicenter Phase III Randomized Study J Natl Cancer Inst, February 21, 2001; 93(4): 300 - 308. [Abstract] [Full Text] [PDF]

				P. J. Woll, N. Thatcher, L. Lomax, J. Hodgetts, S. M. Lee, P. A. Burt, R. Stout, T. Simms, R. Davies, and R. Pettengell Use of Hematopoietic Progenitors in Whole Blood to Support Dose-Dense Chemotherapy: A Randomized Phase II Trial in Small-Cell Lung Cancer Patients J. Clin. Oncol., February 1, 2001; 19(3): 712 - 719. [Abstract] [Full Text] [PDF]

				H. Ozer, J. O. Armitage, C. L. Bennett, J. Crawford, G. D. Demetri, P. A. Pizzo, C. A. Schiffer, T. J. Smith, G. Somlo, J. C. Wade, et al. 2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines J. Clin. Oncol., October 20, 2000; 18(20): 3558 - 3585. [Full Text] [PDF]

				N. Thatcher, D. J. Girling, P. Hopwood, R. J. Sambrook, W. Qian, and R. J. Stephens Improving Survival Without Reducing Quality of Life in Small-Cell Lung Cancer Patients by Increasing the Dose-Intensity of Chemotherapy With Granulocyte Colony-Stimulating Factor Support: Results of a British Medical Research Council Multicenter Randomized Trial J. Clin. Oncol., January 14, 2000; 18(2): 395 - 395. [Abstract] [Full Text] [PDF]

				S. Leyvraz, L. Perey, G. Rosti, A. Lange, S. Pampallona, R. Peters, Y. Humblet, L. Bosquee, F. Pasini, and M. Marangolo Multiple Courses of High-Dose Ifosfamide, Carboplatin, and Etoposide With Peripheral-Blood Progenitor Cells and Filgrastim for Small-Cell Lung Cancer: A Feasibility Study by the European Group for Blood and Marrow Transplantation J. Clin. Oncol., November 1, 1999; 17(11): 3531 - 3539. [Abstract] [Full Text] [PDF]

				P. M. Anderson, S. N. Markovic, J. A. Sloan, M. L. Clawson, M. Wylam, C. A. S. Arndt, W. A. Smithson, P. Burch, M. Gornet, and E. Rahman Aerosol Granulocyte Macrophage-Colony Stimulating Factor: A Low Toxicity, Lung-specific Biological Therapy in Patients with Lung Metastases Clin. Cancer Res., September 1, 1999; 5(9): 2316 - 2323. [Abstract] [Full Text] [PDF]